Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Tafolecimab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Acute Coronary Syndrome
1 trial -
Tamsulosin Hydrochloride
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Benign Prostatic Hyperplasia
1 trial -
Telbivudine
Chinese University of Hong Kong
Chronic Hepatitis B
1 trial -
Telmisartan
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hypertension
1 trial -
Terlipressin treatment
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Septic Shock
1 trial -
Ticagrelor
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Brain Disease
1 trial -
Tislelizumab combined with Lenvatinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Initially Unresectable Hepatocellular Carcinoma
1 trial -
Topical compound tripterygium
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Active Rheumatoid Arthritis
1 trial -
Topical diclofenac sodium gel
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hand Osteoarthritis
1 trial -
Traditional Chinese Medicine treatment
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Frail Elderly Patients
1 trial -
Tramadol
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hip Fractures
1 trial -
Tranexamic acid (TXA)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Blood Loss
1 trial -
Transesophageal echocardiography
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Critically Ill
1 trial -
Trolamine (Biafine)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Radiation Dermatitis
1 trial -
Tumor Specific Antigen-loaded Dendritic Cells
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Tumor Gastric
1 trial -
UC-MSCs
Xiyuan Hospital of China Academy of Chinese Medical Sciences
2019 Novel Coronavirus Pneumonia
1 trial -
Ulinastatin and Thymosin Ξ±1
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Aortic Dissection
1 trial -
Unfractionated heparin
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Primary PCI
1 trial -
Urapidil
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Aging
1 trial -
Valerian
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Menopausal Women
1 trial -
Village doctor-led tailored health management
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Cardiovascular Diseases
1 trial -
Vitamin A
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Vitamin A Deficiency
1 trial -
Vitamin A
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Retinopathy of Prematurity
1 trial -
Voglibose tablets
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Coronary Heart Disease
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources